| 1 |
24691568 | In silico identification of novel kinase inhibitors targeting wild-type and T315I mutant ABL1 from FDA-approved drugs. | 2014 Jun |
2 |
| 2 |
22846973 | Comparison of the effects of two kinase inhibitors, sorafenib and dasatinib, on chronic lymphocytic leukemia cells. | 2012 |
1 |
| 3 |
20337484 | Analysis of imatinib and sorafenib binding to p38alpha compared with c-Abl and b-Raf provides structural insights for understanding the selectivity of inhibitors targeting the DFG-out form of protein kinases. | 2010 May 4 |
2 |
| 4 |
20350535 | BRAF as therapeutic target in melanoma. | 2010 Sep 1 |
1 |
| 5 |
20621496 | The design, synthesis, and evaluation of 8 hybrid DFG-out allosteric kinase inhibitors: a structural analysis of the binding interactions of Gleevec, Nexavar, and BIRB-796. | 2010 Aug 1 |
1 |
| 6 |
19366808 | Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway. | 2009 May 1 |
9 |
| 7 |
17595328 | The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation. | 2007 Sep |
5 |